When Should You Take Your Next Nebido Injection?
Timeline
Timestamp
Topic
00:00
A 51-year-old man switching from Sustanon 250 to Nebido asks when his next testosterone undecanoate injection should occur and whether testosterone levels at weeks eight and ten can guide the timing.
02:00
Dr. O’Connor explains that Nebido and Aveed contain testosterone undecanoate, an exceptionally long-acting testosterone ester with pharmacokinetics that differ substantially from Sustanon, enanthate, and cypionate.
04:10
The loading phase is explained, including why a second testosterone undecanoate injection is given six weeks after the first and why reaching steady state takes several months.
06:44
Dr. O’Connor explains why checking levels at weeks eight and ten after only one Nebido injection can be misleading and discusses shorter-acting testosterone formulations when greater dosing control or microdosing is desired.
14:20
The discussion returns to loading versus maintenance dosing, trough testing, and how subsequent testosterone undecanoate intervals can be individualized after evaluating levels and progression toward steady state.
16:50
Dr. O’Connor broadens the discussion beyond testosterone levels to blood pressure, kidney function, red blood cells, prostate health, diabetes, proteinuria, erections, mood, and the ABCDs™.
Video Summary
A 51-year-old man asks how to time Nebido injections after switching from Sustanon 250. Dr. O’Connor explains that testosterone undecanoate behaves very differently from shorter-acting testosterone esters because its long elimination half-life requires a loading phase and several months before reaching steady state.
He explains that checking testosterone at weeks eight and ten after only the first injection does not properly account for Nebido’s pharmacokinetics. The standard approach discussed uses an initial injection followed by another loading injection six weeks later, with subsequent trough testing and maintenance intervals individualized once drug levels become more stable.
Dr. O’Connor also questions whether this very long-acting formulation is ideal for someone who wants precise control or microdosing, discussing Sustanon, testosterone enanthate, and testosterone cypionate as alternatives. Beyond testosterone levels, he emphasizes monitoring blood pressure, kidney health, red blood cells, prostate health, diabetes, proteinuria, erections, mood, and the broader ABCDs™.
Drug Callouts
Drug
Description
Nebido / Aveed (Testosterone Undecanoate)
Testosterone undecanoate is the central formulation discussed, sold as Nebido in many countries and Aveed in the United States. Dr. O’Connor explains its unusually long elimination half-life, loading phase, delayed steady state, large-volume injection, and individualized maintenance intervals.
Sustanon 250
The member is switching from Sustanon 250 because he dislikes fluctuations between injections. Dr. O’Connor contrasts its shorter pharmacokinetics with testosterone undecanoate and discusses dose concentration when comparing testosterone formulations.
Testosterone Enanthate
Testosterone enanthate is discussed as a shorter-acting alternative that allows smaller and more frequent injections when a man on TRT wants greater control over peaks, troughs, and dosing.
Testosterone Cypionate
Testosterone cypionate is discussed alongside enanthate as a shorter-acting TRT formulation that can be administered in smaller doses rather than relying on the prolonged kinetics of testosterone undecanoate.
Mounjaro
The member reports using Mounjaro for controlled type 2 diabetes. Dr. O’Connor uses his metabolic history to emphasize that TRT management should include diabetes, kidney, cardiovascular, and broader cardiometabolic monitoring.
Condition Callouts
Condition
Description
Hypogonadism
The member reports mixed primary and secondary hypogonadism with a pre-TRT total testosterone around 257. His underlying hypogonadism is the reason testosterone replacement is being continued while the formulation and dosing interval are reconsidered.
Hypertension
The member has treated hypertension, which Dr. O’Connor considers important when managing long-term testosterone therapy. Blood pressure remains part of the broader cardiovascular monitoring needed when adjusting TRT formulations and exposure.
Type 2 Diabetes
The member has type 2 diabetes treated with Mounjaro. Dr. O’Connor emphasizes that glycemic control, kidney health, proteinuria, cardiovascular risk, and other ABCDs™ remain important regardless of which testosterone formulation is used.
Key Takeaways
- Testosterone undecanoate has much longer pharmacokinetics than Sustanon, enanthate, or cypionate and should not be managed as though the formulations are interchangeable.
- Nebido uses a loading phase before longer maintenance intervals because the drug takes several months to approach steady state.
- Testing testosterone too early after only the first Nebido injection may not provide a reliable basis for determining the long-term maintenance interval.
- Trough testosterone levels become more useful when interpreted alongside the loading schedule, steady state, symptoms, and individual pharmacokinetics.
- Shorter-acting testosterone formulations may provide greater dosing flexibility for men who prefer smaller and more frequent injections.
- TRT monitoring should extend beyond testosterone levels to blood pressure, kidney function, red blood cells, metabolic health, prostate health, erections, and mood.